Factors associated with pregnancy outcome in anti‐<scp>TNF</scp> treated women with inflammatory bowel disease

Seirafi, Mariam; Vroey, Bénédicte De; Amiot, Aurélien; Seksik, Philippe; Roblin, Xavier; Allez, Matthieu; Peyrin–Biroulet, Laurent; Marteau, Philippe; Cadiot, Guillaume; Laharie, David; Boureille, Arnaud; Vos, Martine De; Savoye, Guillaume; Rahier, Jean–François; Carbonnel, Franck; Bonaz, Bruno; Colombel, Jean–Frédéric; Bouhnik, Yoram

doi:10.1111/apt.12833

Cited by 89 publications

(75 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[23][24][25][26][27][28]34,35,39,41,[43][44][45][46][47][48][49][50][51] Also excluded were case reports or small case series (n < 10), or manuscripts where there was incomplete information on birth outcomes such that ORs could not be calculated. [79][80][81][82][83][84][85][86] Of the studies with repeat population groups, 27,29,30,36,45,46,49,51,79,80,82,[84][85][86][87][88][89][90][91] the most recent study was selected for inclusion provided data could be extracted. A total of six studies met the final selection criteria for inclusion in the meta-analysis.…”

Section: Studies Retrievedmentioning

confidence: 99%

“…A total of six studies met the final selection criteria for inclusion in the meta-analysis. [46][47][48]50,51,92 …”

Section: Studies Retrievedmentioning

confidence: 99%

“…Four studies were prospective, 47,50,51,92 1 was retrospective 48 and 1 study was both. 46 Four described pregnancy outcomes in a population of both CD and UC 46,48,50,92 and 1 in a CD-only population. 47,51 The studies identified IBD patients and treatment exposure through medical records, 46,48,50 national registries, 47,48,51 national teratology services 51,92 and GETAID centres.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…46 Four described pregnancy outcomes in a population of both CD and UC 46,48,50,92 and 1 in a CD-only population. 47,51 The studies identified IBD patients and treatment exposure through medical records, 46,48,50 national registries, 47,48,51 national teratology services 51,92 and GETAID centres. 46 Birth outcomes were identified from medical records, 46,48,50,51,92 interviews, 47 telephone interviews, 46,48,51,92 questionnaires 47,48 and blinded dysmorphological examination.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…47,51 The studies identified IBD patients and treatment exposure through medical records, 46,48,50 national registries, 47,48,51 national teratology services 51,92 and GETAID centres. 46 Birth outcomes were identified from medical records, 46,48,50,51,92 interviews, 47 telephone interviews, 46,48,51,92 questionnaires 47,48 and blinded dysmorphological examination. 51 The treatment exposures included ADA-only; 51 IFX-only; 47 IFX and ADA; 50,92 and IFX, ADA and CZP.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis

Shihab

Yeomans

Cruz

2016

ECCOJC

View full text Add to dashboard Cite

Background and Aims: Inflammatory bowel disease (IBD) commonly affects women during their reproductive years, leading to concerns regarding pregnancy outcomes and therapeutic safety. The aim of this study was to assess the risks associated with anti-tumour necrosis factor α (anti-TNFα) therapy for pregnancy outcomes, including rates of congenital abnormality, based on published studies. Methods: Published studies were screened from on-line databases and international meeting abstracts. A meta-analysis was performed for adverse pregnancy outcomes (APOs), congenital abnormalities (CAs), preterm birth (PTB) and low birth weight (LBW). The prevalence of CAs was compared with whole-population pooled registry data. Results: In women exposed to anti-TNFα the pooled odds ratio for APOs was 1.14 (95% confidence interval [CI] 0.73-1.78; p = 0.55) compared with disease-matched controls. The pooled odds ratios for CAs, PTB and LBW were 0.89 (0.37-2.13; p = 0.79), 1.21 (0.74-2.00; p = 0.45) and 1.36 (0.77-2.38; p = 0.29) respectively. The rate of CAs in TNFα-exposed women was not statistically different from that in population-wide registries (difference 0.4%, 95% CI −2.0 to +2.7). Conclusions: Anti-TNFα therapy does not increase the risk of APOs, CAs, PTB or LBW compared with disease-matched controls. Furthermore, the risk of CAs is not increased when published prevalence data are compared with data for the general population. These findings may offer some reassurance for women and physicians regarding the safety profile of anti-TNFα during pregnancy in IBD.

show abstract